Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast lesion excision with needle biopsy device leaves residual carcinoma -- RSNA study.

This article was originally published in The Gray Sheet

Executive Summary

EXCISION WITH BIOPSY NEEDLE LEAVES RESIDUAL CARCINOMA in 73% of cases, researcher Laura Liberman, MD, Memorial Sloan-Kettering Cancer Center, New York City, said Dec. 2 at the Radiological Society of North America annual conference in Chicago. Reporting results of a study that used Johnson & Johnson's Mammotome percutaneous breast needle biopsy system, Liberman stated: "In this series of cancers in which percutaneous breast biopsy results in the complete removal of the mammographic lesion, surgery revealed residual carcinoma in 73%," or 11 of 15 cases, Liberman noted.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel